Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: a case report

Dig Dis Sci. 2009 Jun;54(6):1369-72. doi: 10.1007/s10620-008-0476-7. Epub 2008 Sep 4.

Authors

Poonam Mishra¹, Amanda DeVoss, Rish Pai, John Hart, Donald M Jensen

Affiliation

¹ Center for Liver Diseases, The University of Chicago, Chicago, IL 60637, USA.

PMID: 18770036
DOI: 10.1007/s10620-008-0476-7

No abstract available

MeSH terms

Antiviral Agents / administration & dosage
Antiviral Agents / adverse effects
Antiviral Agents / therapeutic use
Dose-Response Relationship, Drug
Genotype
Hepacivirus / genetics*
Hepatitis C, Chronic / blood
Hepatitis C, Chronic / drug therapy*
Hepatitis C, Chronic / virology
Humans
Interferon alpha-2
Interferon-alpha / administration & dosage
Interferon-alpha / adverse effects*
Interferon-alpha / therapeutic use*
Liver / enzymology*
Liver / pathology
Male
Middle Aged
Polyethylene Glycols / administration & dosage
Polyethylene Glycols / adverse effects*
Polyethylene Glycols / therapeutic use*
Recombinant Proteins
Ribavirin / administration & dosage
Ribavirin / therapeutic use
Transaminases / blood*
Viral Load

Substances

Antiviral Agents
Interferon alpha-2
Interferon-alpha
Recombinant Proteins
Polyethylene Glycols
Ribavirin
Transaminases
peginterferon alfa-2a